Invasive surgical procedures provide the unique ability to record and stimulate neurons within precisely localized brain structures in humans. Human studies using invasive technology are often constrained by a limited number of patients and resources available to implement complex experimental protocols and are rarely aggregated in a manner that addresses research questions with appropriate statistical power. Therefore, this RFA seeks applications to assemble diverse, integrated, multi-disciplinary teams that cross boundaries of interdisciplinary collaboration to overcome these fundamental barriers and to investigate high-impact questions in human neuroscience. Projects should maximize opportunities to conduct innovative in vivo neuroscience research made available by direct access to brain recording and stimulating from invasive surgical procedures.
The National Institute on Aging invites revision applications to ongoing NIA-supported Cooperative Agreements in the area of the genetics of Alzheimer's Disease and Alzheimer's Disease Related Dementias (AD/ADRD). This Funding Opportunity Announcement (FOA) invites applications specific to sample acquisition, genome wide association studies, whole genome sequencing, quality control checking, variant calling, and data calling that will support the generation of data for the Alzheimer's Disease Sequencing Project Follow-Up Study.
This Funding Opportunity Announcement (FOA) invites applications to provide infrastructure support for advancing development of specific high-priority areas of behavioral and social research of relevance to Alzheimer's disease and Alzheimer's disease related dementias (AD/ADRD). The infrastructure support will facilitate research networks through meetings, conferences, small-scale pilots, short-term educational opportunities (such as intensive workshops, summer institutes, or visiting scholar programs), and dissemination to encourage growth and development of specified priority areas and build resources for advancing aging-relevant research in the field at large. Network applications are limited to the following areas: (1) AD/ADRD care and services research, and (2) the coordination of international studies conducting the Harmonized Cognitive Assessment Protocol.
Recent advances in endovascular thrombectomy offer a new opportunity to reconsider neuroprotective agents as adjunctive therapies to extend the time window for reperfusion and to improve long-term functional outcome. The purpose of this funding opportunity announcement (FOA) issued by NINDS is to invite applications for the Coordinating Center (CC) for the NIH Stroke Preclinical Assessment Network (SPAN). SPAN will facilitate testing of up to 6 promising neuroprotective drugs or interventions to be given prior to or at the time of reperfusion in experimental models of ischemic stroke (e.g., transient middle cerebral artery occlusion). The CC will work with the awarded network sites (RFA-NS-18-033) and will provide centralized administrative oversight and coordination of all aspects of the network. If successful, this network will accelerate the identification of the most promising neuroprotective therapies for future pivotal clinical trials and span the gap between preclinical and clinical testing, in a cost-and time-effective fashion.
The Brain Research through Advancing Innovative Neurotechnologies (BRAIN) Initiative is aimed at revolutionizing neuroscience through development and application of innovative technologies to map neural circuits, monitor and modulate their activity, and understand how they contribute to thoughts, sensations, emotions and behavior. NIH has issued a variety of Funding Opportunity Announcements (FOAs) that will support projects that apply technologies to understand neural circuit function in the context of specific circuits, resulting in a diverse portfolio of research into the fundamental biology of nervous system function.
The purpose of this announcement is to notify the research community that NIH welcomes BRAIN Initiative applications targeting central nervous system nociceptive and pain circuits, as appropriate to the goals and requirements of specific BRAIN Initiative FOAs. Pain conditions represent an important public health problem and NIH continues to support research into pain pathologies through normal Institute and Center appropriations. However, pain and nociception are also components of normal nervous system function, and the BRAIN Initiative is committed to understanding pain circuits along with brain circuits underlying other sensory, motor, cognitive and emotional functions. It is expected that the unique opportunities of the BRAIN Initiative will enable production of detailed maps of pain circuits, and the adoption of powerful new tools for monitoring and modulating pain circuit activity, leading to significant advances in the understanding of pain and nociception.
For a list of past and open BRAIN Initiative FOAs, see https://braininitiative.nih.gov/funding/.
This Funding Opportunity Announcement (FOA) encourages applications for Silvio O. Conte Centers for Basic Neuroscience or Translational Mental Health Research. The NIMH seeks teams of researchers working at different levels of analysis and employing integrative, novel, and creative experimental approaches to address high-risk, high-impact questions in basic neuroscience research, or in translational research with the primary objectives of: (a) advancing the state of the science in basic brain and behavior research that will uncover and dissect the underlying mechanisms that will ultimately provide the foundation for understanding mental disorders; (b) supporting the integration and translation of basic and clinical neuroscience research on severe mental illnesses; and/or (c) advancing our understanding of the neurobehavioral developmental mechanisms and trajectories of psychopathology that begin in childhood and adolescence. The Conte Centers program is intended to support interdisciplinary basic neuroscience or translational research demonstrating an extraordinary level of synergy, integration, and potential for advancing the state of the field. This program is intended only for projects that could not be achieved using other, more standard grant mechanisms. The Conte Centers program also provides an opportunity to establish interdisciplinary basic neuroscience or translational research experiences for students and post doctorates.
This Funding Opportunity Announcement (FOA) invites applications that seek to enhance existing transcriptome and proteome data sets by revealing oscillatory patterns of gene expression in aging and in Alzheimer's disease (AD), by uncovering their molecular significance, and by identifying rhythmic gene and/or protein profiles associated with the risk for AD. Outcomes of this research may suggest novel opportunities for translational research to allow development of individualized, optimized treatment based on circadian phase and amplitude.
The BrightFocus Foundation provides research funds for U.S. and international researchers pursuing high-risk studies that illuminate areas for which there currently is little understanding, helping to bring to light crucial knowledge about Alzheimer's disease, glaucoma, and macular degeneration. The organization's mission is to save mind and sight by funding innovative research worldwide and by promoting better health through education.
To that end, the foundation is accepting applications for its Alzheimer's Disease Research and National Glaucoma Research programs.
1) Alzheimer's Disease Research: Grants of up to $300,000 over three years will be awarded to researchers for innovative investigator-initiated research projects. The program is designed to give scientists the opportunity to develop the preliminary data necessary to be considered competitive for larger government or corporate types of sponsorship. Applications must be received no later than October 18, 2017.
2) National Glaucoma Program: Grants of up to $150,000 over two years will be awarded to researchers for innovative investigator-initiated glaucoma-related research projects. The program is designed to give scientists the opportunity to develop the preliminary data necessary to be considered competitive for larger government or corporate types of sponsorship.
Typically these awards are made to junior investigators, or to more established investigators who are proposing particularly innovative research.
This Funding Opportunity Announcement (FOA) is associated with the Beau Biden Cancer MoonshotSM Initiative that is intended to accelerate cancer research. The purpose of this FOA is to establish Centers of collaborating investigators with the goal of identifying and advancing research opportunities for translating immunotherapy concepts for children and adolescents with cancer toward clinical applications. Specifically, this FOA targets the following area designated as a scientific priority by the Blue Ribbon Panel (BRP): Recommendation (B) that calls for the establishment of a pediatric immunotherapy translational science network. The network was envisioned by the BRP as focusing on identifying new targets for immunotherapies, developing new pediatric immunotherapy treatment approaches (e.g., cancer vaccines, cellular therapy, combinations of immunotherapy agents, and others), and defining the biological mechanisms by which pediatric tumors evade the immune system. The Pediatric Immunotherapy Discovery and Development Network (PI-DDN) Centers will address and implement these BRP recommendations.
Made possible through a 12-year, $50 million commitment from the Amgen Foundation, Amgen Scholars allows undergraduates from across the globe to participate in cutting-edge research opportunities at world-class institutions. 17 leading institutions across the U.S., Europe and Japan currently host the summer program.
Undergraduate participants benefit from undertaking a research project under top faculty, being part of a cohort-based experience of seminars and networking events, and taking part in a symposium in their respective region (U.S., Europe or Japan) where they meet their peers, learn about biotechnology, and hear from leading scientists.
-- No previous research experience is necessary and you do not need to be a biology major to apply.
-- You do not need to currently attend one of the 17 host institutions to participate in the program.
-- During the program, students work full-time on independent research projects under the guidance of a research scientist.
-- Amgen Scholars have opportunities to conduct research, analyze data, present research results, network with other undergraduates with similar research interests, and develop working relationships with faculty mentors and other research staff.
-- Financial support is a critical component of the Amgen Scholars Program. Please note that details vary by host institution. See each institution's Amgen Scholars Program website for more information.
The Ohio Department of Higher Education (ODHE) will make strategic investments to support expanded opportunities for students in Science, Technology, Engineering, Mathematics and Medical (STEMM) fields. The investments will directly impact the ability of the state of Ohio to
educate and train students to meet Ohio's career and job opportunities today and tomorrow. Choose Ohio First provides scholarships to students in innovative academic programs developed by Ohio's two-year and four-year, public and private colleges and universities, along
with their business partners. The scholarships connect students to work-based learning experiences and careers in STEMM fields in order to recruit and retain these students in Ohio. Choose Ohio First is part of a strategic effort to deepen Ohio's economic strength by increasing the talent pipeline for STEMM-related industries, including computer science, through degree and certificate completion.
The purpose of this funding opportunity announcement (FOA) is to support clinical studies that will fill gaps in the design of upcoming clinical trials in rare neurological or neuromuscular diseases by validating clinical outcome measures or biomarkers, or by characterizing cohorts of relevant patients.Through the support of trial readiness studies, NINDS expects to accelerate the initiation of clinical trials for rare diseases and to increase the likelihood of success in those trials.
The purpose of this Funding Opportunity Announcement (FOA) is to invite applications (via limited competition) for SPARC Comprehensive Functional Mapping of Neuroanatomy and Neurobiology of Organs. These projects will comprehensively provide data for developing detailed, predictive functional and anatomical neural circuit maps for neural control of major functions of organs and their functionally-associated structures.
This Funding Opportunity Announcement (FOA) solicits grant applications in two related but distinct areas.The first area is in the development and testing of novel tools and methods of neuromodulation that go beyond the existing variations on magnetic or electrical stimulation, and that represent more than an incremental advance over existing electromagnetic approaches. The second distinct area that this FOA seeks to encourage is the optimization of existing electrical and magnetic stimulation methods.
The focus of this Funding Opportunity Announcement (FOA) is to better understand how existing non-invasive neuromodulation devices affect brain circuity. This information should shed light on dose/response relationships that could be used for neuroscience applications and clinical interventions.
The purpose of this FOA is to invite innovative research pre-applications from applicants who have an interest in submitting an application to "Stimulating Peripheral Activity to Relieve Conditions (SPARC): Technologies to Understand the Control of Organ Function by the Peripheral Nervous System (OT2)", companion announcement RFA-RM-16-003. This NIH Funding Opportunity Announcement (FOA) solicits pre-applications to develop new and/or enhance existing tools and technologies to be used to elucidate the neurobiology and neurophysiology underlying autonomic control of organs in health or disease, which will ultimately inform next generation neuromodulation therapies. These two-year projects will facilitate technology development for neural mapping activities through the NIH SPARC Common Fund program.
The purpose of this FOA is to invite innovative research pre-applications from applicants who have an interest in submitting an application to "Stimulating Peripheral Activity to Relieve Conditions (SPARC): Technologies to Understand the Control of Organ Function by the Peripheral Nervous System (OT2)", companion announcement RFA-RM-16-003. This NIH Funding Opportunity Announcement (FOA) solicits pre-applications to develop new and/or enhance existing tools and technologies to be used to elucidate the neurobiology and neurophysiology underlying autonomic control of organs in health or disease, which will ultimately inform next generation neuromodulation therapies. These two-year projects will facilitate technology development for neural mapping activities through the NIH SPARC Common Fund program.
The purpose of this graduate-level training program is to improve the health of infants, children, and adolescents who have, or are at risk for developing, autism spectrum disorder (ASD) or other neurodevelopmental and other related disabilities (DD), by expanding interdisciplinary training opportunities for graduate-level trainees from a wide variety of professional disciplines.
This Funding Opportunity Announcement (FOA) encourages transdisciplinary research that will leverage cognitive neuroscience to improve traditional measurement of cognitive impairment following cancer treatment, often referred to as chemobrain. A better understanding of the acute- and late-term cognitive changes following exposure to adjuvant chemotherapy and molecularly-targeted treatments, including hormonal therapy, for non-central nervous system tumors can inform clinical assessment protocols with downstream implications for survivorship care plans.
The purpose of this funding opportunity announcement (FOA) is to invite applications for Clinical Centers (Hubs) in Strategies to Innovate EmeRgENcy Care Clinical Trials Network (SIREN).SIREN will enable conduct of high-quality, multi-site clinical trials to improve the outcomes for patients with neurologic, cardiac, respiratory, and hematologic, and trauma emergency events. SIREN will consist of one Clinical Coordinating Center (CCC), one Data Coordinating Center (DCC) and up to 10 clinical centers (Hubs). A Hub will typically be an academic center or tertiary referral center which will actively enroll patients into every clinical trial performed in SIREN, regardless of disease focus.A Hub will additionally provide scientific leadership and administrative oversight to its multiple satellite sites ("Spokes").Together the Hub and Spokes will provide access to a large and varying patient population for clinical trials. SIREN will implement a total of at least four large (1,000 patient) simple, pragmatic clinical trials in the emergency department and pre-hospital settings. The clinical trials will be meritorious, peerreviewed projects which will be awarded under separate funding announcements.
The purpose of this Funding Opportunity Announcement (FOA) is to inform the scientific community of the pain research interests of the various Institutes and Centers (ICs) at the National Institutes of Health (NIH) and to stimulate and foster a wide range of basic, clinical, and translational studies on pain as they relate to the missions of these ICs. New advances are needed in every area of pain research, from the micro perspective of molecular sciences to the macro perspective of behavioral and social sciences. Although great strides have been made in some areas, such as the identification of neural pathways of pain, the experience of pain and the challenge of treatment have remained uniquely individual and unsolved. Furthermore, our understanding of how and why individuals transition to a chronic pain state after an acute injury is limited. Research to address these issues conducted by interdisciplinary and multidisciplinary research teams is strongly encouraged, as is research from underrepresented, minority, disabled, or women investigators.